Product Information Sheet for NR-2632

Polyclonal Anti-Vaccinia Virus (immune globulin G, Human)

Catalog No. NR-2632

(DynPort Vaccine Company LLC Part No. 0062-0001)
This reagent is the property of the U.S. Government.

For research use only. Not for human use.

Contributor:

U.S. Department of Defense Joint Vaccine Acquisition Program

Product Description:

Vaccinia Immune Globulin Intravenous (VIGIV) is an immune globulin preparation derived from pooled human plasma collected from donors who received booster immunizations with the Dryvax® smallpox vaccine. Pooled plasma was fractionated by ethanol precipitation and modified to yield a product intended for intravenous administration. Nanofiltration and a solvent-detergent viral inactivation process were also used. VIGIV consists primarily of immune globulin G with trace amounts of immune globulin A and immune globulin M. This product will not be launched for marketing and is being made available through BEI Resources for basic research as well as research and development projects.

Material Provided:

Each vial contains 50 mL of VIGIV stabilized with 5% sucrose and 1% human albumin. The total immunoglobulin G concentration in mg per mL is shown on the Certificate of Analysis.

Packaging/Storage:

VIGIV was packaged aseptically in 50 mL glass vials. The product is provided on refrigerated bricks and should be stored at 2°C to 8°C immediately upon arrival. NR-2632 should not be shaken.

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 4th ed. Washington, DC: U.S. Government Printing Office, 1999. HHS Publication No. (CDC) 93-8395. This text is available online at www.cdc.gov/od/ohs/biosfty/bmbl4/bmbl4toc.htm.

The source plasma units used to manufacture this product were tested and found to be negative for hepatitis B surface antigen and antibodies to human immunodeficiency virus (HIV) and hepatitis C virus. Additionally, all plasma pools were negative for HIV RNA by reverse transcriptase polymerase chain reaction. The processes employed in the manufacture of this product have been validated to effectively inactivate or remove potential viruses.

Universal Precautions should be used when handling biological materials derived from human sources, such as NR-2632.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Polyclonal Anti-Vaccinia Virus (immune globulin G, Human), NR-2632."

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine is a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. DynPort Vaccine Company LLC, Frederick, Maryland, personal communication.

ATCC® is a trademark of the American Type Culture Collection.

Support Provided by NIAID

Biodefense and Emerging Infections Research Resources Repository
P.O. Box 4137
Manassas, VA 20108-4137 USA
www.beiresources.org

800-359-7370
Fax: 703-365-2898
E-mail: contact@beiresources.org